Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The company is headquartered in Waltham, Massachusetts and currently employs 300 full-time employees. The company went IPO on 2017-09-28. The firm has developed a switch-control kinase inhibitor platform in kinase biology to execute its strategy to develop a portfolio of medicines. The firm's QINLOCK, is a switch-control kinase inhibitor, engineered using its drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor (GIST). The firm has two additional clinical-stage assets, vimseltinib and DCC-3116. Vimseltinib is an investigational, orally administered, potent, and highly selective switch-control kinase inhibitor of the colony stimulating factor 1 receptor (CSF1R). Vimseltinib is in a pivotal phase III study in patients with tenosynovial giant cell tumor (TGCT). DCC-3116 is an investigational, orally administered, potent, and highly selective switch-control inhibitor of the ULK kinase.

Industry: Pharmaceutical Preparations Peers: CHINOOK THERAPEUTICS, INC. Akero Therapeutics, Inc. Veracyte Inc Catalyst Pharmaceuticals Inc DYNAVAX TECHNOLOGIES CORP Kymera Therapeutics Inc Rhythm Pharmaceuticals Inc SpringWorks Therapeutics, Inc. Zentalis Pharmaceuticals Inc